Century Therapeutics (IPSC) Stock Statistics & Valuation Metrics

Century Therapeutics has a market cap or net worth of $53.91M. The enterprise value is $261.44M.

Century Therapeutics has 86,158,760 shares outstanding. The number of shares has decreased by -2.65% in one year.

Century Therapeutics’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -61.37%.

The current PE Ratio of Century Therapeutics is -0.63. Century Therapeutics’s PEG ratio is -0.07.

In the last 12 months, Century Therapeutics had revenue of 6.59M and earned -126.57M in profits. Earnings per share was -1.61.

In the last 12 months, operating cash flow was -114.51M and capital expenditures 539.00K, giving a free cash flow of -114.13M billion.

Century Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―

Century Therapeutics upcoming earnings date is Aug 7, 2025, Before Open (Confirmed).

Century Therapeutics as a current ratio of 1.50, with Debt / Equity ratio of 16.32%

In the past 12 months, Century Therapeutics has paid 1.79M in taxes.

Century Therapeutics EV to EBITDA ratio is -0.67, with an EV/FCF ratio of -0.68.

Century Therapeutics has $165.12M in cash and marketable securities with $47.79M in debt, giving a net cash position of -$117.33M billion.

Gross margin is -93.71%, with operating margin of -2096.48%, and net profit margin of -1920.87%.

The average price target for Century Therapeutics is $3.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy